ResearcherAir Force Medical UniversityNo recent work listed

He Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3283-8620; OpenAlex author ID A5100420122. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. Co-author DOI 10.1016/j.bbrep.2022.101291 ↗
Mediated Imaging and Improved Targeting of Farnesylthiosalicylic Acid Delivery for Pancreatic Cancer via Conjugation with Near-Infrared Fluorescence Heptamethi… First author DOI 10.1021/acsabm.9b01068 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Changhong Shi · 2 shared papers, 2020–2022 · strength 0.27
- Paper Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. DOI 10.1016/j.bbrep.2022.101291 ↗
- Paper Mediated Imaging and Improved Targeting of Farnesylthiosalicylic Acid Delivery for Pancreatic Cancer via Conjugation wi… DOI 10.1021/acsabm.9b01068 ↗
Jiaze An · 2 shared papers, 2020–2022 · strength 0.27
- Paper Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. DOI 10.1016/j.bbrep.2022.101291 ↗
- Paper Mediated Imaging and Improved Targeting of Farnesylthiosalicylic Acid Delivery for Pancreatic Cancer via Conjugation wi… DOI 10.1021/acsabm.9b01068 ↗
Yong Zhao · 1 shared paper, 2022 · strength 0.16
- Paper Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine. DOI 10.1016/j.bbrep.2022.101291 ↗
Ya Zhao · 1 shared paper, 2020 · strength 0.11
- Paper Mediated Imaging and Improved Targeting of Farnesylthiosalicylic Acid Delivery for Pancreatic Cancer via Conjugation wi… DOI 10.1021/acsabm.9b01068 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.